Indivior (INDV) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
Q3 2026 net revenue rose 13% YoY to $356M; record SUBLOCADE revenue reached $267M, up 22% YoY.
GAAP operating income increased to $180M from $43M and net income to $137M from $42M; adjusted EBITDA rose 76% to $211M.
Action Agenda execution continued ahead of the planned November 2 merger closing with Supernus.
Financial highlights
9M 2026 revenue rose 15% YoY to $1,016M; gross profit was $875M, operating income $477M and GAAP net income $348M.
Q3 GAAP diluted EPS was $1.12 versus $0.33; 9M GAAP diluted EPS was $2.78 versus $0.85.
Q3 non-GAAP net income was $161M ($1.32 diluted EPS); 9M non-GAAP net income was $427M ($3.41 diluted EPS).
GAAP operating expenses fell 33% YoY to $125M; non-GAAP operating expenses fell 29% to $103M.
9M operating cash flow rose to $317M from $194M; cash and equivalents were $305M at September 30, while cash and investments totaled $332M.
Outlook and guidance
Standalone FY 2026 guidance: revenue $1,295M–$1,365M; SUBLOCADE revenue $1,010M–$1,050M; non-GAAP operating expenses $430M–$450M; adjusted EBITDA $700M–$740M.
Guidance assumes no material change in key exchange rates versus 2025 averages; it ceases to apply if the merger closes November 2.
Rest-of-World revenue is expected to decline substantially after market exits; Q4 capex is expected to be $10M, primarily for the Raleigh facility.
Liquidity is expected to cover anticipated cash needs for at least 12 months, conditional on sustained sales and no material change in collections and rebate-payment timing.
Latest events from Indivior
- Merger-related share issuance approved; adjournment proposal was unnecessary.INDV
EGM 2026 - Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies.INDV
Corporate presentation - Q2 2026 saw record results and a merger to form a CNS leader with $2.2B revenue and $888M EBITDA.INDV
Q2 2026 & Merger - SUBLOCADE's growth accelerates with DTC and commercial gains as diversification plans advance.INDV
Jefferies Global Healthcare Conference 2026 - All proposals, including director elections and auditor ratification, were approved.INDV
AGM 2026 - Q1 2026 delivered record EBITDA, 19% revenue growth, and raised guidance on SUBLOCADE strength.INDV
Q1 2026 - Strong financial results, U.S. redomicile, and robust governance mark a pivotal year.INDV
Proxy filing - SUBLOCADE growth, cost cuts, and organizational overhaul drive the 2025–2026 strategy.INDV
Morgan Stanley 23rd Annual Global Healthcare Conference - SUBLOCADE growth drove FY 2024 gains, but 2025 faces a 17% revenue decline from SUBOXONE Film erosion.INDV
Q4 2024